Early Reports on the Prognostic Implications and Immunotherapeutic Potentials of Cd34 Rich Cord Whole Blood Transfusion in Advanced Breast Cancer with Severe Anemia

  • Niranjan Bhattacharya


Anemia is the commonest comorbidity, which prevents an aggressive and effective treatment initiation in case of advanced cancer. It increases with the progression of the disease.1 Severe anemia can cause subsequent tumor cell hypoxia, which can reduce the tumorocidal effect of each modality of treatment including radiation.


Cord Blood Advanced Breast Cancer Umbilical Cord Blood Invasive Lobular Carcinoma Government Hospital 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The Department of Science and Technology, Government of West Bengal, supported the investigator with a research grant during his tenure at Bijoygarh State Hospital from 1999 to 2006. The author gratefully acknowledges the support of the patients who volunteered for this study. The guidance of Prof. K. L. Mukherjee of Biochemistry, and Prof. M. K. Chhetri, the former Director of Health Services, West Bengal, is also acknowledged.


  1.  1.
    Crouch Z, DeSantis ER. Use of erythropoietin-stimulating agents in breast cancer patients: a risk review. Am J Health Syst Pharm. 2009;66(13):1180-1185. Review.CrossRefPubMedGoogle Scholar
  2. 2.
    Mith RE Jr, Tchekmedyian S. Practitioners’practical model for managing cancer elated anemia. Oncology (Huntingt). 2002;16(9 Suppl 10):55-63.Google Scholar
  3. 3.
    Pirker R, Wiesenberger K, Pohl G, Minar W. Anemia in lung cancer: clinical impact and management. Clin Lung Cancer. 2003;5(2):90-97.CrossRefPubMedGoogle Scholar
  4. 4.
    Tchekmedyian NS. Anemia in cancer patients: significance, epidemiology, and current therapy. Oncology (Huntingt). 2002;16(9 Suppl 10):17-24.Google Scholar
  5. 5.
    Steensma DP. Management of anemia in patients with cancer. Curr Oncol Rep. 2004;6(4):297-304.CrossRefPubMedGoogle Scholar
  6. 6.
    Kolesar JM. Novel approaches to anemia associated with cancer and chemotherapy. Am J Health Syst Pharm. 2002;59(15 Suppl 4):S8-S11.PubMedGoogle Scholar
  7. 7.
    Harrison LB, Shasha D, Homel P. Prevalence of anemia in cancer patients undergoing radiotherapy: prognostic significance and treatment. Oncology. 2002;63(Suppl 2):11-18.CrossRefPubMedGoogle Scholar
  8. 8.
    Ludwig H, Fritz E. Anemia of cancer patients: patient selection and patient stratification for epoetin treatment. Semin Oncol. 1998;25(3 Suppl 7):35-38.PubMedGoogle Scholar
  9. 9.
    BCSH Blood Transfusion Task Force. Guideline for the gamma irradiation of the blood components for the prevention of the transfusion associated graft vs host disease. Transfus Med. 1996;6:261.CrossRefGoogle Scholar
  10. 10.
    Goodnough T. Transfusion medicine – blood conservation – second of two parts. N Engl J Med. 1999;340(7):525-533.CrossRefPubMedGoogle Scholar
  11. 11.
    Tscherning-Casper C, Papadogiannakis N, Anvret M, et al. The trophoblastic epithelial barrier is not infected in full-term placentae of human immunodeficiency virus-seropositive mothers undergoing antiretroviral therapy. J Virol. 1999;73(11):9673-9678.PubMedGoogle Scholar
  12. 12.
    Bhattacharya N. Placental umbilical cord whole blood transfusion: a safe and genuine blood substitute for patients of the under-resourced world at emergency. J AM Coll Surg. 2005;200(4):557-563.CrossRefPubMedGoogle Scholar
  13. 13.
    Bhattacharya N, Mukherjee KL, Chettri MK, Banerjee T, Mani U, Bhattacharya S. A study report of 174 units of placental umbilical cord whole blood transfusion in 62 patients as a rich source of fetal hemoglobin supply in different indications of blood transfusion. Clin Exp Obstet Gynecol. 2001;28(1):47-52.PubMedGoogle Scholar
  14. 14.
    Hussain SA, Palmer DH, Stevens A, Spooner D, Poole CJ, Rea DW. Role of chemotherapy in breast cancer. Expert Rev Anticancer Ther. 2005;5(6):1095-1110.CrossRefPubMedGoogle Scholar
  15. 15.
    Lee Tzong-Hae, Paglieroni Teresa, Ohto Hitoshi, Holland Paul V, Busch Michael P. Survival of donor leukocyte ­subpopulations in immunocompetent transfusion recipients: frequent long-term microchimerism in severe trauma patients. Blood. 1999;93(9):3127-3139.PubMedGoogle Scholar
  16. 16.
    Utter GH, Owings JT, Lee TH, et al. Blood transfusion is associated with donor leukocyte microchimerism in trauma patients. J Trauma. 2004;57(4):702-707. discussion 707–708.CrossRefPubMedGoogle Scholar
  17. 17.
    Lee TH, Paglieroni T, Utter GH, et al. High-level long-term white blood cell microchimerism after transfusion of ­leukoreduced blood components to patients resuscitated after severe traumatic injury. Transfusion. 2005;45(8):1280-1290.CrossRefPubMedGoogle Scholar
  18. 18.
    Szekeres-Bartho J. Immunological relationship between the mother and the fetus. Int Rev Immunol. 2002;21(6):471-495.CrossRefPubMedGoogle Scholar
  19. 19.
    Carosella ED. HLA-G: fetomaternal tolerance. C R Acad Sci III. 2000;323(8):675-680.PubMedGoogle Scholar
  20. 20.
    Ishitani A, Sageshima N, Lee N, et al. Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition. J Immunol. 2003;171:1376-1384.PubMedGoogle Scholar
  21. 21.
    Sargent IL. Maternal and fetal immune responses during pregnancy. Exp Clin Immunogenet. 1993;10:85.PubMedGoogle Scholar
  22. 22.
    Le Bouteiller P, Rodriguez AM, Mallet V, Girr M, Guillaudeux T, Lenfant F. Placental expression of HLA class I genes. Am J Reprod Immunol. 1996;35:216.PubMedGoogle Scholar
  23. 23.
    McCracken S, Layton JE, Shorter SC, Starkey PM, Barlow DH, Mardon HJ. Expression of granulocyte-colony stimulating factor and its receptor is regulated during the development of the human placenta. J Endocrinol. 1996;149:249-258.CrossRefPubMedGoogle Scholar
  24. 24.
    Lee T-H, Donegan EA, Slichter S, Busch MP. Transient increase in circulating donor leukocytes following allogeneic transfusions in immunocompetent recipients compatible with donor cell proliferation. Blood. 1995;85:1207.PubMedGoogle Scholar
  25. 25.
    Madrigal JA, Cohen SBA, Gluckman E, Charron DJ. Does cord blood transplantation result in lower graft vs host disease.It takes more than two to tango. Hum Immunol. 1997;56:1-5.CrossRefPubMedGoogle Scholar
  26. 26.
    Chang M-DY, Polar JW, Khalili H, et al. Mouse placental macrophages have a decreased ability to present an antigen. Proc Natl Acad Sci USA. 1993;90:452-456.CrossRefGoogle Scholar
  27. 27.
    Roitt I, Brostoff J, Male D. Immunology. 6th ed. London, UK: Mosby; 2001:205-206: Chap. 12.Google Scholar
  28. 28.
    Joshi SS, Vu UE, Lovgren TR, et al. Comparison of phenotypic and functional dendritic cells derived from human umbilical cord blood and peripheral blood mononuclear cells. J Hematother Stem Cell Res. 2002;11(2):337-347.CrossRefPubMedGoogle Scholar
  29. 29.
    Schmitz-Winnenthal FH, Volk C, Z’graggen K, et al. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res. 2005;65(21):10079-10087.CrossRefPubMedGoogle Scholar
  30. 30.
    Joshi AD, Clark EM, Wang P, et al. Immunotherapy of human neuroblastoma using umbilical cord blood-derived effector cells. J Neuroimmune Pharmacol. 2007;2(2):202-212. Epub 2006 Oct 10.CrossRefPubMedGoogle Scholar
  31. 31.
    Migliaccio AR, Alfani E, Di Giacomo V, Cieri M, Migliaccio G. Ex vivo amplification of T cells from human cord blood. Pathol Biol (Paris). 2005;53(3):151-158. Review.Google Scholar

Copyright information

© Springer London 2011

Authors and Affiliations

  • Niranjan Bhattacharya
    • 1
  1. 1.Department of General Surgery, Obstertrics and Gynaecology and Clinical Immunology, Advanced Medical Research InstituteB.P. Poddar Hospital and Vidyasagore HospitalKolkataIndia

Personalised recommendations